Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Is Spironolactone the Preferred Renin–Angiotensin–Aldosterone Inhibitor for Protection Against COVID-19?
Christopher S. Wilcox, Bertram Pitt
Journal of Cardiovascular Pharmacology (2020) Vol. 77, Iss. 3, pp. 323-331
Open Access | Times Cited: 25

Showing 25 citing articles:

Hypertension, a Moving Target in COVID-19
Carmine Savoia, Massimo Volpe, Reinhold Kreutz
Circulation Research (2021) Vol. 128, Iss. 7, pp. 1062-1079
Open Access | Times Cited: 81
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
Peter Kolkhof, Amer Joseph, Ulrich Kintscher
Pharmacological Research (2021) Vol. 172, pp. 105859-105859
Open Access | Times Cited: 56
SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism
Nitin Kumar, Yu Zuo, Srilakshmi Yalavarthi, et al.
Viruses (2021) Vol. 13, Iss. 11, pp. 2209-2209
Open Access | Times Cited: 50
Spironolactone as an adjuvant treatment for COVID-19: a systematic review and meta-analysis
Arman Shafiee, Mohammad Javad Amini, M. Rafiei, et al.
Future Virology (2025), pp. 1-8
Closed Access
Renin–Angiotensin–Aldosterone System: Friend or Foe—The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions
Fedor Šimko, Jaroslav Hrenak, Michaela Adamcová, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 6, pp. 3217-3217
Open Access | Times Cited: 21
Serpin peptidase inhibitor, clade E, member 2 in physiology and pathology: recent advancements
Shutong Wu, Yuchao Yang, Meiling Zhang, et al.
Frontiers in Molecular Biosciences (2024) Vol. 11
Open Access | Times Cited: 3
Combination of spironolactone and DPP-4 inhibitors for treatment of SARS-CoV-2 infection: a literature review
Kamyar Asadipooya, Artin Asadipooya, Reuben Adatorwovor
Archives of Virology (2024) Vol. 169, Iss. 6
Closed Access | Times Cited: 3
Management of Patients With Glucocorticoid-Related Diseases and COVID-19
Irina Chifu, Mario Detomas, Ulrich Dischinger, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 19
The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets
Morley D. Hollenberg, Murray Epstein
Kidney International Supplements (2022) Vol. 12, Iss. 1, pp. 48-62
Open Access | Times Cited: 14
ACE2, the Counter-Regulatory Renin–Angiotensin System Axis and COVID-19 Severity
Filippos Triposkiadis, Αndrew Xanthopoulos, Grigorios Giamouzis, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 17, pp. 3885-3885
Open Access | Times Cited: 17
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?
Fedor Šimko, Tomáš Baka
Clinical Science (2021) Vol. 135, Iss. 8, pp. 1009-1014
Open Access | Times Cited: 15
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease
Bertram Pitt, Rajiv Agarwal, Stefan D. Anker, et al.
JAMA Network Open (2022) Vol. 5, Iss. 10, pp. e2236123-e2236123
Open Access | Times Cited: 11
PTSD as an Endothelial Disease: Insights From COVID-19
Adonis Sfera, Carolina Osorio, Leah Rahman, et al.
Frontiers in Cellular Neuroscience (2021) Vol. 15
Open Access | Times Cited: 13
Association between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis
Jean Kim, Kyle Miyazaki, Parthav Shah, et al.
Healthcare (2022) Vol. 10, Iss. 4, pp. 645-645
Open Access | Times Cited: 10
Combination of spironolactone and sitagliptin improves clinical outcomes of outpatients with COVID-19: a prospective cohort study
Mohammad Ali Davarpanah, Reuben Adatorwovor, Yasaman Mansoori, et al.
Journal of Endocrinological Investigation (2023) Vol. 47, Iss. 1, pp. 235-243
Open Access | Times Cited: 5
Integrative analysis of functional genomic screening and clinical data identifies a protective role for spironolactone in severe COVID-19
Henry C. Cousins, Adrienne Sarah Kline, Chengkun Wang, et al.
Cell Reports Methods (2023) Vol. 3, Iss. 7, pp. 100503-100503
Open Access | Times Cited: 4
Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis—A Randomized Placebo Controlled Clinical Trial
Katarzyna Kotfis, Igor Karolak, Kacper Lechowicz, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 2, pp. 200-200
Open Access | Times Cited: 7
White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome
Abdalla Z. Mohamed, Jorge do Campo, Peter Del Fante, et al.
Fatigue Biomedicine Health & Behavior (2024), pp. 1-11
Open Access | Times Cited: 1
Commentary: Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells
Fedor Šimko, Tomáš Baka
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 3
Renin-Angiotensin-Aldosterone System
Robert C. Speth
Elsevier eBooks (2021), pp. 528-569
Closed Access | Times Cited: 3
When Off Target Effects Are On Target: The Role Of Spironolactone In Patients With COVID-19
Christopher S. Wilcox, Bertram Pitt
(2021)
Open Access | Times Cited: 2
Combination of Spironolactone and Sitagliptin Improves Clinical Outcomes of Outpatients with COVID-19: A Prospective Cohort Study
Mohammad Ali Davarpanah, Reuben Adatorwovor, Yasaman Mansoori, et al.
Authorea (Authorea) (2022)
Open Access | Times Cited: 1
The Effect of Potassium Canrenoate (Mineralocorticoid Receptor Antagonist) on the Markers of Inflammation in the Treatment of COVID-19 Pneumonia and Fibrosis—A Secondary Analysis of Randomized Placebo-Controlled Clinical Trial
Igor Karolak, Rafał Hrynkiewicz, Paulina Niedźwiedzka‐Rystwej, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14247-14247
Open Access
Involvement of fibrinolysis in COVID-19 pathogenesis
Tetsumei Urano
Japanese Journal of Thrombosis and Hemostasis (2021) Vol. 32, Iss. 1, pp. 46-50
Open Access
Role of renin-angiotensin-aldosterone system inhibitors in the development and evolution of Covid-19
Juan Miyahira
Revista Médica Herediana (2021) Vol. 32, Iss. 1, pp. 3-4
Open Access
Page 1

Scroll to top